Profiel
Dr. Bianca Brundel is Chief Scientific Officer at NYKEN BV.
He received his graduate degree from the University of Amsterdam and a doctorate degree from the University of Groningen.
Eerdere bekende functies van Bianca Brundel
| Bedrijven | Functie | Einde |
|---|---|---|
Nyken BV
 Nyken BV Pharmaceuticals: GenericHealth Technology Nyken BV develops heat-shock-protein drugs for treatment of chronic diseases. Its products include NYK-1001, a drug that is used for the treatment of gastric discomfort and gastric bleeding in China, Japan, and internationally, NYK-1005, a chemical derivative that is used for atrial myocyte screening and drug identifying discovery system and NYK-1007, an early drug candidate used in heat shock proteins. The company was founded by Herman Steen in 2009 and is headquartered in Groningen, the Netherlands. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Bianca Brundel
| University of Amsterdam | Graduate Degree |
| University of Groningen | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
Nyken BV
Nyken BV Pharmaceuticals: GenericHealth Technology Nyken BV develops heat-shock-protein drugs for treatment of chronic diseases. Its products include NYK-1001, a drug that is used for the treatment of gastric discomfort and gastric bleeding in China, Japan, and internationally, NYK-1005, a chemical derivative that is used for atrial myocyte screening and drug identifying discovery system and NYK-1007, an early drug candidate used in heat shock proteins. The company was founded by Herman Steen in 2009 and is headquartered in Groningen, the Netherlands. | Health Technology |